Medline, Inc. Medline Brand — Segment adjusted EBITDA decreased by 7.8% to $765.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.8%, from $830.00M to $765.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates improved operational efficiency or higher margins, while a decrease suggests rising costs or margin compression.
Measures the operational profitability of the Medline Brand segment by excluding interest, taxes, depreciation, amortiza...
Standard 'Adjusted EBITDA' metric used across the healthcare manufacturing industry to compare operational performance.
mdln_segment_medline_brand_segment_adjusted_ebitda| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $676.00M | $676.00M | $676.00M | $676.00M | $817.25M | $817.25M | $817.25M | $817.25M | $830.00M | $765.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +20.9% | +0.0% | +0.0% | +0.0% | +1.6% | -7.8% |
| YoY Change | — | — | — | — | +20.9% | +20.9% | +20.9% | +20.9% | +1.6% | -7.8% |